Objectives:
To determine the correlations of ADP-induced platelet-inhibition rate (ADP-PIR) and CYP2C19 genotypes with carotid plaque types in acute ischemic stroke (AIS). Unstable carotid plaques are implicated in AIS. Clopidogrel (commonly prescribed in AIS) produces adenosine diphosphate (ADP)-induced platelet inhibition, and is metabolized by CYP2C19.
Methods:
We retrospectively evaluated the data of AIS patients treated at our hospital during 2019–2022, and administered maintenance clopidogrel (75 mg/d). Carotid plaques, ADP-PIR, and CYP2C19 genotypes were assessed using color Doppler ultrasonography, thromboelastography, and polymerase chain reaction assays, respectively. Multivariate logistic regression and receiver operating characteristic (ROC) curve analyses were conducted.
Results:
Of 692 study patients, 378 (54.6%) and 128 (18.5%) had unstable and stable carotid plaques, respectively. Multivariate logistic regression identified PIR and CYP2C19 genotype as independent risk factors for stable carotid plaque (PIR, OR: 0.984, 95% CI: 0.974–0.995, p=0.003; intermediate metabolizer, OR: 0.158, 95% CI: 0.066–0.379, p<0.001; poor metabolizer, OR: 0.584, 95% CI: 0.155–2.206, p=0.428) and unstable carotid plaque (PIR, OR: 0.957, 95% CI: 0.949–0.966, p<0.001; intermediate metabolizer, OR: 0.151, 95% CI: 0.063–0.362, p<0.001; poor metabolizer, OR: 0.145, 95% CI: 0.051–0.416, p<0.001). Areas under the ROC curve for predicting unstable and stable carotid plaques were 0.700 (PIR) and 0.716 (CYP2C19 genotype), and 0.631 (PIR) and 0.650 (CYP2C19 genotype), respectively.
Conclusion:
The PIR and CYP2C19 genotype are correlated with and may predict carotid plaque types in AIS.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: | July 16, 2025
NeuroScience